Last reviewed · How we verify
NCT06550726
High-resolution Multi-parametric Magnetic Resonance Imaging for Focal Epilepsy
NA trial testing Magnetic Resonance Imaging in Epilepsies, Partial in 66 participants. Currently enrolling.
31 August 2027
Quick facts
| Lead sponsor | Chinese University of Hong Kong |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | diagnostic |
| Enrollment | 66 |
| Start date | 1 September 2024 |
| Primary completion | 31 August 2027 |
| Estimated completion | 31 August 2028 |
| Sites | 1 location across Hong Kong |
Drugs / interventions tested
- Magnetic Resonance Imaging
Conditions studied
- Epilepsies, Partial — all drugs for Epilepsies, Partial →
Sponsor
Chinese University of Hong Kong
Who can join
Eligibility, any sex, with Epilepsies, Partial. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Patients with focal epilepsy often have diagnostic difficulties as their culprit for seizures are difficult to be picked up using conventional imaging. The current study is to investigate the utility of advanced MRI sequences on detection of subtle lesions accountable for focal epilepsy.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06550726
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Magnetic Resonance Imaging
Trials testing the same drug.
- NCT03192007 — Multi-Parametric MRI for Renal Transplantation · not yet recruiting
- NCT07229339 — Zipalertinib With Carboplatin and Pemetrexed for the Treatment of Resectable, Stage II-IIIB, Non-Small Cell Lung Cancer · Phase 2 · not yet recruiting
- NCT07441681 — Comparing Radiation Plus Cetuximab to Radiation Plus Chemotherapy in People With Head and Neck Cancer Who Cannot Receive · Phase 3 · not yet recruiting
- NCT07147231 — Testing the Effectiveness of the Anti-cancer Drug Pidnarulex (CX-5461), in Combination With Another Anti-cancer Drug Cem · Phase 1, PHASE2 · recruiting
- NCT06448286 — PH Weighted Chemical Exchange Saturation Transfer MRI-Based Surgical Resection to Improve Survival in Patients With Glio · Phase 3 · not yet recruiting
Other recruiting trials for Epilepsies, Partial
Currently open trials in the same condition.
- NCT06967012 — A Clinical Study on the Efficacy and Safety of Zonisamide as a First Add-On Treatment in Epileptic Seizures · Phase 4 · recruiting
- NCT06590896 — Safety of Cenobamate in Japanese Subjects With Partial Onset Seizures · Phase 2 · recruiting
- NCT05248269 — Thermocoagulation in Drug Resistant Focal Epilepsy · NA · active not recruiting
- NCT04309812 — Transcranial Direct Current to Treat Epilepsy at Home · NA · active not recruiting
- NCT03949478 — Treating Postictal Symptoms Using Ibuprofen and Nifedipine · Phase 2 · recruiting
Other Chinese University of Hong Kong trials
Trials by the same sponsor.
- NCT07508644 — RSV Vaccination to Reduce Recurrent AECOPD · Phase 4 · not yet recruiting
- NCT07230457 — Plasma MTB cfDNA Before Bronchoscopy · not yet recruiting
- NCT07288671 — Nostalgia Intervention on Alleviating Loneliness Amongst Older Adults · NA · not yet recruiting
- NCT07256457 — Postoperative Pulmonary Function Assessment Based on Deep Learning Study · NA · not yet recruiting
- NCT06904209 — Can Artificial Intelligence Reduce Consumption of Standard High Volume Bowel Preparation Regimen Among Older Population, · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06550726 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Chinese University of Hong Kong
- Last refreshed: 3 April 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06550726.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing